Abuelgasim Khadega A, Albuhayri Bandar, Munshi Rayan, Mugairi Areej Al, Alahmari Bader, Gmati Giamal, Salama Hind, Alzahrani Mohsen, Alhejazi Ayman, Alaskar Ahmed, Damlaj Moussab
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
King Abdulaziz Medical City, Oncology Department, Riyadh 11426, Saudi Arabia.
Leuk Res Rep. 2020 Jun 9;14:100206. doi: 10.1016/j.lrr.2020.100206. eCollection 2020.
The prognosis of acute myeloid leukemia (AML) remains poor. Among 180 patients, the median age was 53 (14-88) years. The overall 2-year disease free survival (DFS) was 28.6% (+/- 3.4), 47.7% (+/- 6.6%) for ≤ 40, 23.6% (+/- 5.8%) for 41-60 and 11.7% (+/- 4.2%) for ≥61 (< 0.0001). The overall 2-year survival (OS) was 45.3% (+/- 3.8%), 78.6% (+/- 5.5%) for ≤40, 43.5% (+/- 6.9%) for 41-60 and 15.8% (+/- 4.8%) for ≥61 (< 0.0001). Induction outcome of ≥61 was best in high dose chemotherapy (HDC) group ( < 0.0001). Only those ≤40 had durable DFS and OS. HDC appears to improve the outcome of older AML patients.
急性髓细胞白血病（AML）的预后仍然很差。180例患者的中位年龄为53岁（14 - 88岁）。总体2年无病生存率（DFS）为28.6%（±3.4），年龄≤40岁者为47.7%（±6.6%），41 - 60岁者为23.6%（±5.8%），≥61岁者为11.7%（±4.2%）（<0.0001）。总体2年生存率（OS）为45.3%（±3.8%），年龄≤40岁者为78.6%（±5.5%），41 - 60岁者为43.5%（±6.9%），≥61岁者为15.8%（±4.8%）（<0.0001）。≥61岁患者在高剂量化疗（HDC）组中的诱导缓解结果最佳（<0.0001）。只有年龄≤40岁的患者有持久的DFS和OS。HDC似乎能改善老年AML患者的预后。
